This website is intended for healthcare professionals only.

Hospital Healthcare Europe
Hospital Pharmacy Europe     Newsletter          

Cardiovascular disease burden substantial after acute COVID-19 infection

The cardiovascular disease burden among survivors of an acute COVID-19 infection is substantial even for individuals not hospitalised

The cardiovascular disease burden among those who survived an infection with COVID-19 appears to be huge and present even for those not originally hospitalised during the acute phase of their infection. This is according to a study by researchers from the Clinical Epidemiology Center, Research and Development Service, Missouri, US.

Studies among patients who were originally hospitalised because of a COVID-19 infection have found higher rates of subsequent cardiovascular disease. In fact, it has been found that COVID-19 is a risk factor for acute myocardial infarction and ischaemic stroke

However, many of the studies linking infection with COVID-19 and subsequent adverse cardiovascular outcomes relate to patients who were originally hospitalised because of their infection. As a result, these individuals might have had a number of co-morbidities that increased their cardiovascular disease risk burden.

In the absence of a comprehensive assessment of the cardiovascular effects of COVID-19 at 12 months and among individuals treated in different care settings, the authors of the current study, set out to address this important knowledge gap.

The team used the US department of Veterans Affairs national healthcare databases to build a cohort of individuals who had survived for at least 30 days after an acute COVID-19 infection and two other groups; one consisting of Veterans Affairs members with no evidence of a COVID-19 infection and a historical cohort (i.e., prior to the current pandemic) from 2017.

The researchers followed these three cohorts to estimate the risks of pre-specified incident cardiovascular outcomes and further analysed these outcomes with respect to the existence of prior cardiovascular disease and according to their particular care settings.

Cardiovascular disease burden and COVID-19

This is a sponsored advert: Please read the information below
Cogora InRead Image
Access our CME/CPD courses anytime, anywhere, and study at your own pace
This is a sponsored advert: Please read the information above

The overall sample included 153,760 individuals with a mean age of 61.4 years (89% male) who had COVID-19, 5,637,647 contemporary controls and 5,859,411 historical controls. All three groups were followed for a median of 347.3 days.

Among those with COVID-19, there was a 52% increased risk of stroke (hazard ratio, HR = 1.52, 95% CI 1.43 – 1.62) compared to contemporary controls and a 49% increased risk of a transient ischaemic attack (HR = 1.49).

Increased risks were also found for dysrhythmias including atrial fibrillation (HR = 1.71) and sinus tachycardia (HR = 1.84) and thromboembolic disorders such as a pulmonary embolism (HR = 2.93) and deep vein thrombosis (HR = 2.09).

The authors then used the composite endpoint of major adverse cardiovascular events (MACE) which included myocardial infarction, stroke and any of the pre-specified outcomes. Compared to the contemporary control group, the risk of MACE was 55% higher (HR = 1.55) and for any cardiovascular outcome (HR = 1.63).

The cardiovascular disease burden after a COVID-19 infection was also higher than for contemporary controls among those who did not have prior cardiovascular disease.

Furthermore, these risks were still elevated, compared to those in the contemporary group, irrespective of the care setting where patients were treated, e.g., non-hospitalised, hospitalised and intensive care .

The authors concluded that their study had demonstrated a substantial cardiovascular disease burden among those who had experienced an acute infection with COVID-19, even among those without prior disease and in any care setting in comparison to those without an infection.

Xie Y et al. Long-term cardiovascular outcomes of COVID-19 Nat Med 2022